Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
Conclusion: In our model, osimertinib was unlikely to be cost-effective compared to placebo for stage IB to IIIA, EGFR-mutated, completely resected NSCLC patients from the perspective of a U.S. payer at a WTP threshold of $150,000 per QALY. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 28, 2024 Category: Drugs & Pharmacology Source Type: research

Phytochemical analysis and anticancer effect of Camellia oleifera bud ethanol extract in non-small cell lung cancer A549 cells
Camellia oleifera is a medicine food homology plant widely cultivated in the Yangtze River Basin and southern China due to its camellia oil. Camellia oleifera bud and fruit exist simultaneously, and its bud is largely discarded as waste. However, C. oleifera bud has been used in traditional Chinese medicine to treat a variety of ailments. Thus, the purpose of this study was to identify the chemical components of C. oleifera bud ethanol extract (EE) and first evaluate its anticancer effects in non-small cell lung cancer A549 cells. Based on UHPLC-Q-Orbitrap-MS analysis, seventy components were identified. For anticancer act...
Source: Frontiers in Pharmacology - March 28, 2024 Category: Drugs & Pharmacology Source Type: research

Case weighted power priors for hybrid control analyses with time-to-event data
Biometrics. 2024 Mar 27;80(2):ujae019. doi: 10.1093/biomtc/ujae019.ABSTRACTWe develop a method for hybrid analyses that uses external controls to augment internal control arms in randomized controlled trials (RCTs) where the degree of borrowing is determined based on similarity between RCT and external control patients to account for systematic differences (e.g., unmeasured confounders). The method represents a novel extension of the power prior where discounting weights are computed separately for each external control based on compatibility with the randomized control data. The discounting weights are determined using th...
Source: Cancer Control - March 27, 2024 Category: Cancer & Oncology Authors: Evan Kwiatkowski Jiawen Zhu Xiao Li Herbert Pang Grazyna Lieberman Matthew A Psioda Source Type: research

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort
This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.PMID:38534959 | DOI:10.3390/curroncol31030126 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Simon Nannini Florian Guisier Hubert Curcio Charles Ricordel Pierre Demontrond Safa Abdallahoui Seyyid Baloglu Laurent Greillier Christos Chouaid Roland Schott Source Type: research

Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.ABSTRACTUsing digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: David J Stewart Katherine Cole Dominick Bosse Stephanie Brule Dean Fergusson Tim Ramsay Source Type: research

Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective
Conclusions: This study is, to our knowledge, the largest single-institution study in Canada looking at lung cancer survival during the COVID-19 pandemic. Our study looks at overall survival in the advanced/metastatic setting of NSCLC during the COVID-19 pandemic. We have previously reported on treatment pattern changes and increased wait times for NSCLC patients during the pandemic. In this study, we report that the advanced/metastatic subgroup had both an increase in the 6-month mortality rate and worsening overall survival during this same time period. Although there was no statistical difference in the proportion of pa...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Jason Agulnik Goulnar Kasymjanova Carmela Pepe Jennifer Friedmann David Small Lama Sakr Hangjun Wang Alan Spatz Khalil Sultanem Victor Cohen Source Type: research

Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre
Conclusions: This study emphasizes the need for the expansion of regional resources to meet the clinical needs of advanced NSCLC patients treated at a regional cancer centre which uses an off-site molecular laboratory.PMID:38534948 | DOI:10.3390/curroncol31030115 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Katelyn E Fleming Ava Hupel Hamid Mithoowani Tea Lulic-Kuryllo Mario Valdes Source Type: research

Wedge Resection versus Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors ≤8 mm
The objective of this study was to evaluate the overall survival of patients with ≤8 mm non-small cell lung cancer (NSCLC) who undergo wedge resection versus stereotactic body radiation therapy (SBRT). Kaplan-Meier analysis, multivariable Cox proportional hazards modeling, and propensity score-matched analysis were performed to evaluate the overall survival of patients with ≤8 mm NSCLC in the National Cancer Database (NCDB) from 2004 to 2017 who underwent wedge resection versus patients who underwent SBRT. The above-mentioned matched analyses were repeated for patients with no comorbidities. Patients who were coded in ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Arian Mansur Zain Saleem Jorind Beqari Camille Mathey-Andrews Alexandra L Potter James Cranor Alexandra T Nees Deepti Srinivasan Margaret E Yang Chi-Fu Jeffrey Yang Hugh G Auchincloss Source Type: research

A deep learning model for translating CT to ventilation imaging: analysis of accuracy and impact on functional avoidance radiotherapy planning
ConclusionUsing deep-learning techniques, CTVISyn generated from planning CT exhibited a moderate-to-high correlation with CTVI4DCT. The CTVISyn-guided plans were comparable to the CTVI4DCT-guided plans, effectively reducing pulmonary toxicity in patients while maintaining acceptable plan quality. Further prospective trials are needed to validate these findings. (Source: Japanese Journal of Radiology)
Source: Japanese Journal of Radiology - March 27, 2024 Category: Radiology Source Type: research

Reply – Letter to the editor: Different Computed Tomography Parameters for Defining Myosteatosis in Patients with Advanced Non-Small Cell Lung Cancer
(Source: Clinical Nutrition ESPEN)
Source: Clinical Nutrition ESPEN - March 27, 2024 Category: Nutrition Authors: Runjie Li, Ming Yang Tags: Letter to the Editor Source Type: research

BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
AbstractBRAF mutations are found in 1 –5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been confirmed that targeted therapy with dabrafenib + trametinib is effective in patients with metastatic NSCLC carrying BRAF V600E mutations. Preclinical studies have shown that da brafenib + trametinib may also have inhibitory effects on some types of non-V600E mutations, especially some class II BRAF mutations. However, the efficacy of dabrafenib + trametinib on non-V600E mutant NSCLC in clinical practice only exists in some case reports. Here, we report a c...
Source: Journal of Cancer Research and Clinical Oncology - March 27, 2024 Category: Cancer & Oncology Source Type: research

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
This study aimed to evaluate the effect of early dose reduction of osimertinib on efficacy and safety.  This was a retrospective study including patients withEGFR-mutated NSCLC who were started on osimertinib as the first-line therapy between August 2018 and December 2021. Patients whose doses were reduced to less than 80  mg/day within 6 months of osimertinib initiation or started at 40 mg/day were defined as the dose reduction group. The primary endpoint was progression-free survival (PFS). Factors affecting PFS were explored using the Cox proportional hazards model. A total of 85 patients were included in this study...
Source: Investigational New Drugs - March 27, 2024 Category: Drugs & Pharmacology Source Type: research

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
Lung cancer is the leading cause of cancer deaths worldwide attributing to 1.8 million deaths [1]. Surgical resection is the standard of care for resectable early-stage non-small cell lung carcinoma (NSCLC) [2]. 25 –70 % of patients eventually develop a relapse after complete resection [3]. Neoadjuvant therapy is defined as any therapy delivered prior to definitive surgical therapy intended to increase the cure rate [4]. Neoadjuvant therapy has many benefits in its potential to increase survival. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 27, 2024 Category: Cancer & Oncology Authors: Christopher Grant, Misako Nagasaka Source Type: research

Cancers, Vol. 16, Pages 1302: An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
Mark Vincent Immune-checkpoint inhibitors (ICIs) have an established role in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC). ICIs have now entered the paradigm of early-stage NSCLC. The recent evidence shows that the addition of ICI to neoadjuvant chemotherapy improves the pathological complete response (pCR) rate and survival rate in early-stage resectable NSCLC and is now a standard of care option in this setting. In this regard, stage III NSCLC merits special consideration, as it is heterogenous and requires a multidisciplinary approach to management. As the neoadjuvant approach...
Source: Cancers - March 27, 2024 Category: Cancer & Oncology Authors: Saurav Verma Daniel Breadner Abhenil Mittal David A. Palma Rahul Nayak Jacques Raphael Mark Vincent Tags: Review Source Type: research

N1-positive non-small cell lung cancer: surgeons ’ perspective before undertaking a major resection
AbstractAmong various reasons for a rise in surgical referrals for locally advanced non-small cell lung cancer, few are improved clinical-pathological staging, better understanding of oncological driver mutation, and aggressive neoadjuvant treatment options. These cases with positive ipsilateral bronchopulmonary lymph nodes are intriguing subset where multiple treatment options have been explored to improve disease-free survival. Targeted neoadjuvant therapy followed by surgical resection is becoming a new norm and surgeons are referred these complex cases. This narrative review is highlighting the importance of proper pre...
Source: Indian Journal of Thoracic and Cardiovascular Surgery - March 27, 2024 Category: Cardiovascular & Thoracic Surgery Source Type: research